

**REMARKS**

Claim 7 have been amended so as clarify the donor, acceptor, product, and enzyme. Claim 7 is also narrowed so as to be directed to cell-free conditions only and to add the further step of removing the released CMP. Claim 8 has been amended and Claim 9 has been added so as to further clarify the acceptor of Claim 7. Support for the clarified donors is found in the Specification on page 22, Table 1. Support for the clarified acceptors is found in Figure 4. Support for the clarified product is found in Figures 4 and 5. Support for the enzyme is found in Figures 1 and 3. Support for the cell-free conditions is found in Figure 4 and in the specification in the paragraph that bridges pages 5 and 6. Support for the CMP removal step is found in the specification at the top of page 16.

**Rejection under 35 U.S.C. 112, second paragraph:**

Claims 7 and 8 have been rejected under 35 U.S.C. 112, second paragraph as indefinite. Applicant's amendments have obviated this basis for rejection.

**Rejection under 35 U.S.C. 112, first paragraph:**

Claims 7 and 8 have been rejected under 35 U.S.C. 112, first paragraph as unsupported by the specification. Applicant's amendments have obviated this basis for rejection.

**Rejection under 35 U.S.C. 102(b):**

Claims 7 and 8 have been rejected under 35 U.S.C. 102(b), as anticipated by Vann and by Steenbergen. Applicant's amendments have obviated this basis for

rejection by adding a CMP removal step. The CMP removal step is unanticipated by the cited prior art. The cited prior art failed to disclose the structure of the products made and achieved only low yields. Applicant has overcome the problem of low yields by adding a CMP removal step. Applicant's better yields enabled him to better characterize the acceptor specificity and the product structures. Applicant's better yields also enhanced the accessibility and availability of the products.

Summary:

Applicant's amendments have rendered claims 7 and 8 clear, novel, and fully supported by the specification. The Examiner is requested to examine claims 7-9.

Respectfully submitted,



Donald G. Lewis  
Reg. No. 28,636  
The Scripps Research Institute  
10550 N. Torrey Pines Road TPC-8  
San Diego, CA 92037  
December 4, 2003  
(858) 784-2937